| Speakers from |
 |
|
Abbott
Amgen
AstraZeneca
Bayer Healthcare
Bio-Modeling Systems
Definiens AG
EMEA
F. Hoffmann-La Roche
GlaxoSmithKline
Ingenuity Systems
Innsbruck University
Institute for Women’s Health, UCL
Johnson & Johnson
Lundbeck
Merck
Millipore
National Institute of Standards & Technology
NeuroSearch
Novartis
Olink Bioscience
Pfizer
Rules Based Medicine
Ryerson University
Schering-Plough
The Critical Path Institute
The Institute of Cancer Research
UCB Group
University College Dublin
Uppsala University
|
|
|
|
|
| Featured Speakers |
|
|
|
Stewart Bates,
Director Biomarker Discovery, Biopharm R&D, GlaxoSmithKline
|
 |
|
|
Chris Chamberlain,
Medical Director Personalised Medicine, AstraZeneca
|
|
|
|
Dinesh De Alwis,
Senior Research Advisor, Group Leader Global PK/PD, Europe, Eli Lilly
|
|
|
|
Nicholas Dracopoli,
Vice President, Biomarkers, Centocor Research & Development, Johnson & Johnson
|
|
|
|
Bruno Flamion,
Chair, CHMP Scientific Advice Working Party, EMA
|
|
|
|
Patricia Hurley,
Head of Project Management and Biomarkers Division, ERA Consulting (UK) Ltd
|
|
|
|
Vicki Ikin,
Clinical Biomarker Scientist Group Manager, AstraZeneca
|
|
|
|
Vicki Ikin,
Clinical Biomarker Scientist Group Manager, AstraZeneca
|
|
|
|
Mark Jones,
Director Experimental Medicine (Biomarkers), New Medicines, UCB New Medicines
|
|
|
|
Debra Klatte,
Director, Integrative Biology, Boehringer Ingelheim
|
|
|
|
Donna L. Mendrick,
Director, Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration
|
|
|
|
Niroshan Ramachandran,
Senior Manager, Research and Development, Life Technologies
|
|
|
|
Stefan Scherer,
Global Biomarker Head F. Hoffmann-La Roche / Genentech
|
|
|
|
Arndt Schmitz,
Founding Scientist, Research Biobank, Bayer Schering Pharma AG
|
|
|
|
Peter Smith,
Senior Scientist II, Oncology, Millennium Pharmaceuticals
|
|
|
|
Birgitte Søgaard,
Divisional Director, Clinical Pharmacology and Translational Medicine, Lundbeck
|
|
|
|
Maarten Van Roy,
Associate Scientist, Pharmacology, Ablynx
|
|
|
|
Gabriel Vargas,
Biomarker Expert & Head of the CNS Clinical Biomarker Group F.Hoffmann-La Roche
|
|
|
|
|
|
.JPG)
